Efficacy and Safety of Clarithromycin as Treatment for Mediterranean Spotted Fever in Children: A Randomized Controlled Trial | Zendy

Antonio Cascio | Zendy; Claudia Colomba | Zendy; Domenico Di Rosa | Zendy; L Salsa | Zendy; L. di Martino | Zendy; Lucina Titone | Zendy

Open Access

Efficacy and Safety of Clarithromycin as Treatment for Mediterranean Spotted Fever in Children: A Randomized Controlled Trial

Author(s) -

Antonio Cascio,

Claudia Colomba,

Domenico Di Rosa,

L Salsa,

L. di Martino,

Lucina Titone

Publication year - 2001

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/321864

Subject(s) - clarithromycin , medicine , chloramphenicol , randomized controlled trial , antibiotics , antibacterial agent , adverse effect , microbiology and biotechnology , biology , helicobacter pylori

Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research